Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
It is estimated that one-third of our country’s population has some form of these disorders
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Cagrilintide represents a novel approach to obesity management
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
Subscribe To Our Newsletter & Stay Updated
